Chris Potter / Flickr Creative Commons

The latest drug pricing controversy comes from Marathon Pharmaceuticals, a company that received federal approval Thursday for an old drug, deflazacort, to treat patients who are at least 5 years old and have the rare Duchenne muscular dystrophy.

The Wall Street Journal and others reported the annual list price will be $89,000. Wanda Moebius, a spokesperson for Marathon, told Axios the net annual amount that Marathon will receive after rebates and discounts will be closer to $54,000 on average.

Here's the catch: Marathon's deflazacort, a steroid, was already approved outside of the United States and can be bought for a lot less. The drug can be bought for less than $2,000 annually from the United Kingdom or Canada. Moebius justified the U.S. price, saying Marathon "can only sell the drug in the U.S. in this population." She added, "Anyone who needs this drug will get this drug."

Why this matters: Marathon's drug will get seven years of monopoly pricing, among other perks for so-called orphan drugs. That's raised the ire of many, who believe this is just another example of egregious drug pricing policy. Rachel Sachs, a law professor at Washington University in St. Louis, put Marathon's move this way:

"This is not acceptable. Full stop. It is the worst sort of gaming that other companies have engaged in over the years."

Go deeper

Pundits react to a chaotic debate: “What a dark event we just witnessed”

The first presidential debate between President Trump and Joe Biden in Cleveland on Tuesday night was a shouting match, punctuated by interruptions and hallmarked by name-calling.

Why it matters: If Trump aimed to make the debate as chaotic as possible with a torrent of disruptions, he succeeded. Pundits struggled to make sense of what they saw, and it's tough to imagine that the American people were able to either.

Trump to far-right Proud Boys: "Stand back and stand by"

Asked to condemn white supremacist violence at the first presidential debate on Tuesday, President Trump said the far-right Proud Boys group should "stand back and stand by," before immediately arguing that violence in the U.S. "is not a right-wing problem. This is a left-wing problem."

Why it matters: Trump has repeatedly been accused of failing to condemn white nationalism and right-wing violence, despite the FBI's assessment that it's the most significant domestic terrorism threat that the country faces. The president has frequently associated antifa and the left-wing violence that has afflicted some U.S. cities with Biden, despite his condemnation of violent protests.

Mike Allen, author of AM
1 hour ago - Politics & Policy

The first Trump v. Biden presidential debate was a hot mess

Photos: Jim Watson and Saul Loeb/AFP via Getty Images

This debate was like the country: Everybody’s talking. Nobody’s listening. Nothing is learned. It’s a mess.

  • We were told President Trump would be savage. Turned out, that was a gross understatement. Even the moderator, Fox News' Chris Wallace, got bulldozed.

Why it matters: Honestly, who the hell knows?